How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?
Identifieur interne : 004070 ( Main/Exploration ); précédent : 004069; suivant : 004071How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?
Auteurs : Paul K. Morrish [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2003-10.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme, Recherche scientifique.
English descriptors
- KwdEn :
- Biological Markers (analysis), Biological transport, Brain (radionuclide imaging), Clinical Trials as Topic, Clinical trial, Disease Progression, Dopamine, Evolution, Human, Humans, Indication, Neuroprotective Agents (therapeutic use), PET, Parkinson Disease (drug therapy), Parkinson Disease (radionuclide imaging), Parkinson disease, Parkinson's disease, Positron emission tomography, Reproducibility, Reproducibility of Results, SPECT, Scientific research, Sensitivity, Sensitivity and Specificity, Single photon emission tomography, Technique, Tomography, Emission-Computed, Tomography, Emission-Computed, Single-Photon, Validity, neuroprotection.
- MESH :
- chemical , analysis : Biological Markers.
- drug therapy : Parkinson Disease.
- radionuclide imaging : Brain, Parkinson Disease.
- chemical , therapeutic use : Neuroprotective Agents.
- Clinical Trials as Topic, Disease Progression, Humans, Reproducibility of Results, Sensitivity and Specificity, Tomography, Emission-Computed, Tomography, Emission-Computed, Single-Photon.
Abstract
To use functional imaging data as indices of disease progression, it is essential that methods are valid. It is not possible for that validation to come from pathology and the methods can only gain validity from the relationship to clinical indices of progression. Validity as a measurement of disease progression depends upon sensitivity to clinical progression, low scan‐to‐scan error, and resilience to confounding effects. Data from the available dopamine transporter (DAT) positron emission tomography (PET) and single photon emission computed tomography (SPECT) studies are examined for these three key factors. Presently, there are insufficient data to enable the satisfactory design of neuroprotection studies and to enable statements on their relevance to disease progression and neuroprotection. The recently completed CALM‐PD neuroimaging study is examined. There is sufficient doubt surrounding the sensitivity, reproducibility, and confounding effects in this study that these data should not be used to formulate a decision on de novo therapy in Parkinson's disease. © 2003 Movement Disorder Society
Url:
DOI: 10.1002/mds.10581
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000C31
- to stream Istex, to step Curation: 000C31
- to stream Istex, to step Checkpoint: 002A00
- to stream PubMed, to step Corpus: 003676
- to stream PubMed, to step Curation: 003676
- to stream PubMed, to step Checkpoint: 003762
- to stream Ncbi, to step Merge: 000B88
- to stream Ncbi, to step Curation: 000B88
- to stream Ncbi, to step Checkpoint: 000B88
- to stream Main, to step Merge: 005C93
- to stream PascalFrancis, to step Corpus: 002347
- to stream PascalFrancis, to step Curation: 000974
- to stream PascalFrancis, to step Checkpoint: 002436
- to stream Main, to step Merge: 005F82
- to stream Main, to step Curation: 004070
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?</title><author><name sortKey="Morrish, Paul K" sort="Morrish, Paul K" uniqKey="Morrish P" first="Paul K." last="Morrish">Paul K. Morrish</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:74396DD88EAD7D20C5EA3F082AC3F767BBB201A6</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1002/mds.10581</idno><idno type="url">https://api.istex.fr/document/74396DD88EAD7D20C5EA3F082AC3F767BBB201A6/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000C31</idno><idno type="wicri:Area/Istex/Curation">000C31</idno><idno type="wicri:Area/Istex/Checkpoint">002A00</idno><idno type="wicri:doubleKey">0885-3185:2003:Morrish P:how:valid:is</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:14531048</idno><idno type="wicri:Area/PubMed/Corpus">003676</idno><idno type="wicri:Area/PubMed/Curation">003676</idno><idno type="wicri:Area/PubMed/Checkpoint">003762</idno><idno type="wicri:Area/Ncbi/Merge">000B88</idno><idno type="wicri:Area/Ncbi/Curation">000B88</idno><idno type="wicri:Area/Ncbi/Checkpoint">000B88</idno><idno type="wicri:doubleKey">0885-3185:2003:Morrish P:how:valid:is</idno><idno type="wicri:Area/Main/Merge">005C93</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:04-0115372</idno><idno type="wicri:Area/PascalFrancis/Corpus">002347</idno><idno type="wicri:Area/PascalFrancis/Curation">000974</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002436</idno><idno type="wicri:doubleKey">0885-3185:2003:Morrish P:how:valid:is</idno><idno type="wicri:Area/Main/Merge">005F82</idno><idno type="wicri:Area/Main/Curation">004070</idno><idno type="wicri:Area/Main/Exploration">004070</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?</title><author><name sortKey="Morrish, Paul K" sort="Morrish, Paul K" uniqKey="Morrish P" first="Paul K." last="Morrish">Paul K. Morrish</name><affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Hurstwood Park Neurological Centre, Princess Royal Hospital, East Sussex</wicri:regionArea><wicri:noRegion>East Sussex</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2003-10">2003-10</date><biblScope unit="vol">18</biblScope><biblScope unit="issue">S7</biblScope><biblScope unit="supplement">7</biblScope><biblScope unit="page" from="S63">S63</biblScope><biblScope unit="page" to="S70">S70</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">74396DD88EAD7D20C5EA3F082AC3F767BBB201A6</idno><idno type="DOI">10.1002/mds.10581</idno><idno type="ArticleID">MDS10581</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Biological Markers (analysis)</term><term>Biological transport</term><term>Brain (radionuclide imaging)</term><term>Clinical Trials as Topic</term><term>Clinical trial</term><term>Disease Progression</term><term>Dopamine</term><term>Evolution</term><term>Human</term><term>Humans</term><term>Indication</term><term>Neuroprotective Agents (therapeutic use)</term><term>PET</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (radionuclide imaging)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Positron emission tomography</term><term>Reproducibility</term><term>Reproducibility of Results</term><term>SPECT</term><term>Scientific research</term><term>Sensitivity</term><term>Sensitivity and Specificity</term><term>Single photon emission tomography</term><term>Technique</term><term>Tomography, Emission-Computed</term><term>Tomography, Emission-Computed, Single-Photon</term><term>Validity</term><term>neuroprotection</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Biological Markers</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Brain</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Disease Progression</term><term>Humans</term><term>Reproducibility of Results</term><term>Sensitivity and Specificity</term><term>Tomography, Emission-Computed</term><term>Tomography, Emission-Computed, Single-Photon</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Dopamine</term><term>Essai clinique</term><term>Evolution</term><term>Homme</term><term>Indication</term><term>Parkinson maladie</term><term>Recherche scientifique</term><term>Reproductibilité</term><term>Sensibilité</term><term>Technique</term><term>Tomographie émission positon</term><term>Tomoscintigraphie émission monophotonique</term><term>Transport biologique</term><term>Validité</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term><term>Recherche scientifique</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To use functional imaging data as indices of disease progression, it is essential that methods are valid. It is not possible for that validation to come from pathology and the methods can only gain validity from the relationship to clinical indices of progression. Validity as a measurement of disease progression depends upon sensitivity to clinical progression, low scan‐to‐scan error, and resilience to confounding effects. Data from the available dopamine transporter (DAT) positron emission tomography (PET) and single photon emission computed tomography (SPECT) studies are examined for these three key factors. Presently, there are insufficient data to enable the satisfactory design of neuroprotection studies and to enable statements on their relevance to disease progression and neuroprotection. The recently completed CALM‐PD neuroimaging study is examined. There is sufficient doubt surrounding the sensitivity, reproducibility, and confounding effects in this study that these data should not be used to formulate a decision on de novo therapy in Parkinson's disease. © 2003 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country></list><tree><country name="Royaume-Uni"><noRegion><name sortKey="Morrish, Paul K" sort="Morrish, Paul K" uniqKey="Morrish P" first="Paul K." last="Morrish">Paul K. Morrish</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004070 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004070 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:74396DD88EAD7D20C5EA3F082AC3F767BBB201A6
|texte= How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?
}}
| This area was generated with Dilib version V0.6.23. |  |